Curaleaf obtains EU medical device certification for its portable cannabis extract inhaler

Curaleaf  announced the certification of a new medical device for cannabis: the continent’s first portable liquid inhalation device for the’precise administration of cannabinoids, simply put, a vape pen.

Developed in collaboration with the company Jupiter Research, the system received the EU Class IIa Medical Device Certification under the Regulation (EU) 2017/745.

A Certified Leap Forward in Medical Cannabis

This new certified inhalation device is equipped with a magnetic cartridge system and a rechargeable power supply enabling consistent and controlled dosing and intended for cannabis extracts.

Boris Jordan, President and Chief Executive Officer of Curaleaf Holdings, explained the importance of this certification:

«Obtaining EU medical certification is more than just a regulatory step—it is a innovation in medical cannabis. »We are proud to offer a device that meets the highest safety and quality standards, and we look forward to helping patients and healthcare providers across Europe and beyond by providing them with a new, precise, and discreet treatment option."

The certification paves the way for the device to be distributed legally in the EU, the United Kingdom, Canada, and Australasia, and thus to millions of potential patients.

Why is this important?

Obtaining medical certification in Europe is a complex process. With this certified nebulizer Class IIa, Curaleaf has reached a milestone that few players in the medical marijuana have achieved: full and complete integration into the field of conventional medicine.

This gives a New legitimacy for cannabinoid therapy, now delivered via a delivery system as reliable as a medical inhaler. This milestone also creates a precedent under the regulations significant. Going forward, other devices could follow suit, opening up a new market for cannabis-based medical devices that are smart, safe, and scalable.

Therapeutic Precision and Controlled Use

The lack of precision in traditional methods (smoking, ingestion) has long been an obstacle to the adoption of medical cannabis. The device developed with Jupiter Research This should fix the problem: controlled dosage, rapid inhalation, magnetic cartridge and rechargeable battery provide reliable, reproducible administration that is tailored to medical protocols.

This will likely make it easier for healthcare professionals to recommend the cannabinoids for conditions such as chronic pain, epilepsy, or anxiety, without ambiguity or stigma.

Its modular design also paves the way for custom formulations, incorporating targeted terpenes, rare cannabinoids or custom formulations. An innovation that is already paving the way for the next step: cannabis-based medicine that is as personalized as it is effective.

Gaining a Head Start in a Market That's Still Unclear

While many European players remain focused on culture or extraction, Curaleaf stands out with a certified product designed for healthcare systems. This positioning gives it a a regulatory lead that is difficult to close, especially in countries such as Germany and the United Kingdom, where patient access is hampered by a lack of appropriate infrastructure.